L-carnitine and acetyl-L-carnitine combined for prevention and treatment of syndromes related to diseases of energy metabolism
US5889055A · kind A · utility
12Cited by
3References
20Claims
0Family size
Inventor
Key dates
| Filing date | Apr 4, 1997 |
| Grant date | Mar 30, 1999 |
| Priority date | — |
| Expiry date | Apr 4, 2017 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/22
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A combination can be of L-carnitine and acetyl-L-carnitine administered orally or as parenteral injection in domesticated animals, especially pet animals, and humans for prevention or treatment of syndromes or diseases arising from dysfunctional energy metabolism. Syndromes involving skeletal and cardiac muscle benefited from L-carnitine, syndromes related to the central nervous system improved with acetyl-L-carnitine. Although the two cofactors do not substitute metabolically for each other effects of the combination are found to be synergistic.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.